UA73081C2 - Amino-terminally truncated mcp-2 as chemokine antagonists - Google Patents

Amino-terminally truncated mcp-2 as chemokine antagonists Download PDF

Info

Publication number: UA73081C2
Authority: UA; Ukraine
Prior art keywords: mcp; truncated; amino; protein; cells
Prior art date: 1997-09-29

Application number

UA2000042499A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-29

Filing date

1998-09-28

Publication date

2005-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA73081(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-28 Application filed by Applied Research Systems filed Critical Applied Research Systems

2005-06-15 Publication of UA73081C2 publication Critical patent/UA73081C2/uk

Links

102000019034 Chemokines Human genes 0.000 title claims abstract description 24
108010012236 Chemokines Proteins 0.000 title claims abstract description 24
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 title abstract description 4
239000005557 antagonist Substances 0.000 title description 5
150000001413 amino acids Chemical group 0.000 claims abstract description 18
201000010099 disease Diseases 0.000 claims abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
230000003042 antagnostic effect Effects 0.000 claims abstract description 8
230000000694 effects Effects 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
125000000539 amino acid group Chemical group 0.000 claims abstract description 4
238000003745 diagnosis Methods 0.000 claims abstract description 3
238000002560 therapeutic procedure Methods 0.000 claims abstract 2
108090000623 proteins and genes Proteins 0.000 claims description 38
102000004169 proteins and genes Human genes 0.000 claims description 29
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
239000013598 vector Substances 0.000 claims description 15
230000003399 chemotactic effect Effects 0.000 claims description 13
108020004414 DNA Proteins 0.000 claims description 11
108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
229940126601 medicinal product Drugs 0.000 claims description 5
102000053602 DNA Human genes 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 2
208000037357 HIV infectious disease Diseases 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
230000033115 angiogenesis Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
239000001963 growth medium Substances 0.000 claims description 2
230000011132 hemopoiesis Effects 0.000 claims description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
208000027866 inflammatory disease Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 1
238000010188 recombinant method Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
102100034871 C-C motif chemokine 8 Human genes 0.000 abstract description 49
239000002299 complementary DNA Substances 0.000 abstract description 5
101710155833 C-C motif chemokine 8 Proteins 0.000 abstract 2
108010055204 Chemokine CCL8 Proteins 0.000 description 46
210000004027 cell Anatomy 0.000 description 37
235000018102 proteins Nutrition 0.000 description 25
235000001014 amino acid Nutrition 0.000 description 17
238000000034 method Methods 0.000 description 17
239000011575 calcium Substances 0.000 description 10
238000000746 purification Methods 0.000 description 8
102400001037 MCP-2(6-76) Human genes 0.000 description 7
101800003624 MCP-2(6-76) Proteins 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
210000001616 monocyte Anatomy 0.000 description 7
102100021943 C-C motif chemokine 2 Human genes 0.000 description 6
101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000035605 chemotaxis Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000001902 CC Chemokines Human genes 0.000 description 3
108010040471 CC Chemokines Proteins 0.000 description 3
108050006947 CXC Chemokine Proteins 0.000 description 3
102000019388 CXC chemokine Human genes 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
101000708735 Homo sapiens Y+L amino acid transporter 1 Proteins 0.000 description 3
102100032726 Y+L amino acid transporter 1 Human genes 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000002559 chemokine receptor antagonist Substances 0.000 description 3
239000003636 conditioned culture medium Substances 0.000 description 3
238000000586 desensitisation Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
102000043805 human CCL8 Human genes 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000011148 porous material Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000523 sample Substances 0.000 description 3
-1 t-butoxycarbonyl Chemical group 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000003277 amino acid sequence analysis Methods 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
230000028550 monocyte chemotaxis Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
108050005711 C Chemokine Proteins 0.000 description 1
102000017483 C chemokine Human genes 0.000 description 1
102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010014423 Chemokine CXCL6 Proteins 0.000 description 1
101710091342 Chemotactic peptide Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000343235 Maso Species 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
239000002556 chemokine receptor agonist Substances 0.000 description 1
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003269 fluorescent indicator Substances 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
238000001698 laser desorption ionisation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000011268 leukocyte chemotaxis Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000030505 negative regulation of chemotaxis Effects 0.000 description 1
230000011242 neutrophil chemotaxis Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

UA2000042499A 1997-09-29 1998-09-28 Amino-terminally truncated mcp-2 as chemokine antagonists UA73081C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97116863A EP0906954A1 (de)	1997-09-29	1997-09-29	Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
PCT/EP1998/006142 WO1999016876A1 (en)	1997-09-29	1998-09-28	Amino-terminally truncated mcp-2 as chemokine antagonists

Publications (1)

Publication Number	Publication Date
UA73081C2 true UA73081C2 (en)	2005-06-15

Family

ID=8227408

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
UA2000042499A UA73081C2 (en)	1997-09-29	1998-09-28	Amino-terminally truncated mcp-2 as chemokine antagonists
UA2000042496A UA73080C2 (en)	1997-09-29	1998-09-28	Amino-terminally truncated rantes as chemokine antagonists

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
UA2000042496A UA73080C2 (en)	1997-09-29	1998-09-28	Amino-terminally truncated rantes as chemokine antagonists

Country Status (28)

Country	Link
US (5)	US6977071B2 (de)
EP (6)	EP0906954A1 (de)
JP (2)	JP4233214B2 (de)
KR (2)	KR100542934B1 (de)
CN (3)	CN1145693C (de)
AR (2)	AR013529A1 (de)
AT (3)	ATE368742T1 (de)
AU (2)	AU750606B2 (de)
BG (2)	BG64757B1 (de)
BR (2)	BR9812394A (de)
CA (2)	CA2305017A1 (de)
CY (1)	CY1110927T1 (de)
CZ (2)	CZ299478B6 (de)
DE (3)	DE69823218T2 (de)
DK (3)	DK1439231T3 (de)
EA (2)	EA003940B1 (de)
EE (2)	EE200000152A (de)
ES (3)	ES2215324T3 (de)
HU (2)	HU226468B1 (de)
IL (2)	IL135351A (de)
NO (2)	NO20001584D0 (de)
NZ (3)	NZ503234A (de)
PL (2)	PL196427B1 (de)
PT (3)	PT1019507E (de)
SK (2)	SK286495B6 (de)
UA (2)	UA73081C2 (de)
WO (2)	WO1999016876A1 (de)
ZA (2)	ZA988676B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6989435B2 (en)	1997-09-11	2006-01-24	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en)	1997-09-11	2006-06-27	Cambridge University Technical Services, Ltd.	Compounds and methods to inhibit or augment an inflammatory response
WO1999028474A2 (en) *	1997-12-01	1999-06-10	The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services	Chemokine variants and methods of use
US7238711B1 (en)	1999-03-17	2007-07-03	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
ES2272329T3 (es) *	1999-10-25	2007-05-01	Pharis Biotec Gmbh	Quimioquinina humana phc-1 procesada.
EP1167527A1 (de) *	2000-06-22	2002-01-02	Euroscreen S.A.	Prozessierte Menschliche Chemokine: PHC-1 und PHC-2
WO2001036459A2 (en) *	1999-11-15	2001-05-25	Forssmann Wolf Georg	Novel use of hcc-2
CA2316405A1 (en) *	2000-05-26	2001-11-26	Ian Clark-Lewis	Modulation of inflammation by protease products
EP1176200A3 (de)	2000-06-20	2005-01-12	Switch Biotech Aktiengesellschaft	Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) *	2000-10-04	2007-02-15	Applied Research Systems	Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) *	2001-03-28	2002-10-02	Rega Inst For Medical Res	Truncating chemokines using dipeptidyl peptidase IV
WO2003051921A1 (en)	2001-12-17	2003-06-26	Applied Research Systems Ars Holding N.V.	Chemokine mutants acting as chemokine antagonists
EP1631680A2 (de) *	2003-05-21	2006-03-08	Bayer HealthCare AG	Diagnostika und therapeutika für dipeptidylpeptidase iv (dpp4) assoziierte erkrangkungen
DE102005049637A1 (de) *	2005-10-14	2007-04-26	Rheinisch-Westfälische Technische Hochschule Aachen	Antagonisten gegen die Interaktion von PF4 und RANTES
CA2695237A1 (en)	2007-08-02	2009-04-30	Novimmune S.A.	Anti-rantes antibodies and methods of use thereof
WO2011097567A1 (en) *	2010-02-08	2011-08-11	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University	Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
JP5975886B2 (ja)	2010-03-11	2016-08-23	ヘルスリサーチインコーポレイテッドＨｅａｌｔｈＲｅｓｅａｒｃｈ，Ｉｎｃ．	Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
TW201718851A (zh) *	2015-09-18	2017-06-01	通用醫院公司	具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CA3101052A1 (en)	2018-05-28	2019-12-05	ORION Biotechnology Switzerland Sarl	Methods of inhibiting cerebral inflammation
US11629196B2 (en)	2020-04-27	2023-04-18	Incelldx, Inc.	Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en)	2020-12-21	2022-08-02	Incelldx, Inc.	Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01265099A (ja)	1987-10-08	1989-10-23	Stichting Rega Vzw	抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) *	1993-11-12	1998-04-14	Dana-Farber Cancer Institute	Chemokine N-terminal deletion mutations
CZ290850B6 (cs) *	1994-12-08	2002-10-16	Glaxo Group Limited	Polypeptid, způsob jeho výroby, kódující DNA nebo RNA, vektor a buňka
AU1532697A (en) *	1996-01-12	1997-08-01	Genetics Institute Inc.	Beta-chemokine, h1305 (mcp-2)
EP0889961A2 (de) *	1996-03-27	1999-01-13	Icos Corporation	Monozyte chemotaktisches protein-5 stoffe und verfahren
FR2748938B1 (fr) *	1996-05-22	1998-07-31	Pasteur Institut	Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) *	1997-09-03	2001-01-02	Gryphon Sciences	N-terminal modifications of RANTES and methods of use

1997
- 1997-09-29 EP EP97116863A patent/EP0906954A1/de not_active Withdrawn
- 1997-12-19 EP EP97122471A patent/EP0905240A1/de not_active Withdrawn
1998
- 1998-03-10 EP EP98104216A patent/EP0905241A1/de not_active Withdrawn
- 1998-09-22 ZA ZA9808676A patent/ZA988676B/xx unknown
- 1998-09-22 ZA ZA9808675A patent/ZA988675B/xx unknown
- 1998-09-28 CN CNB988095696A patent/CN1145693C/zh not_active Expired - Fee Related
- 1998-09-28 EE EEP200000152A patent/EE200000152A/xx unknown
- 1998-09-28 CA CA002305017A patent/CA2305017A1/en not_active Abandoned
- 1998-09-28 NZ NZ503234A patent/NZ503234A/en unknown
- 1998-09-28 HU HU0003563A patent/HU226468B1/hu not_active IP Right Cessation
- 1998-09-28 NZ NZ503235A patent/NZ503235A/xx unknown
- 1998-09-28 KR KR1020007003020A patent/KR100542934B1/ko not_active Expired - Fee Related
- 1998-09-28 PT PT98951476T patent/PT1019507E/pt unknown
- 1998-09-28 BR BR9812394-7A patent/BR9812394A/pt not_active Application Discontinuation
- 1998-09-28 ES ES98947553T patent/ES2215324T3/es not_active Expired - Lifetime
- 1998-09-28 EP EP04007579A patent/EP1439231B1/de not_active Expired - Lifetime
- 1998-09-28 CZ CZ20001146A patent/CZ299478B6/cs not_active IP Right Cessation
- 1998-09-28 KR KR1020007003019A patent/KR100560275B1/ko not_active Expired - Fee Related
- 1998-09-28 EP EP98947553A patent/EP1021541B1/de not_active Expired - Lifetime
- 1998-09-28 HU HU0003505A patent/HU226414B1/hu not_active IP Right Cessation
- 1998-09-28 CN CNB031492991A patent/CN1233415C/zh not_active Expired - Fee Related
- 1998-09-28 UA UA2000042499A patent/UA73081C2/uk unknown
- 1998-09-28 EE EEP200000151A patent/EE200000151A/xx unknown
- 1998-09-28 NZ NZ516027A patent/NZ516027A/en unknown
- 1998-09-28 DE DE69823218T patent/DE69823218T2/de not_active Expired - Lifetime
- 1998-09-28 ES ES04007579T patent/ES2287601T3/es not_active Expired - Lifetime
- 1998-09-28 UA UA2000042496A patent/UA73080C2/uk unknown
- 1998-09-28 DK DK04007579T patent/DK1439231T3/da active
- 1998-09-28 EA EA200000379A patent/EA003940B1/ru not_active IP Right Cessation
- 1998-09-28 DK DK98951476T patent/DK1019507T3/da active
- 1998-09-28 WO PCT/EP1998/006142 patent/WO1999016876A1/en not_active Ceased
- 1998-09-28 AT AT04007579T patent/ATE368742T1/de active
- 1998-09-28 AT AT98951476T patent/ATE263242T1/de active
- 1998-09-28 CA CA002304827A patent/CA2304827A1/en not_active Abandoned
- 1998-09-28 EA EA200000378A patent/EA003942B1/ru not_active IP Right Cessation
- 1998-09-28 DE DE69822856T patent/DE69822856T2/de not_active Expired - Lifetime
- 1998-09-28 SK SK451-2000A patent/SK286495B6/sk not_active IP Right Cessation
- 1998-09-28 AR ARP980104820A patent/AR013529A1/es active IP Right Grant
- 1998-09-28 PL PL339545A patent/PL196427B1/pl not_active IP Right Cessation
- 1998-09-28 AU AU94420/98A patent/AU750606B2/en not_active Ceased
- 1998-09-28 AT AT98947553T patent/ATE264390T1/de active
- 1998-09-28 PL PL339559A patent/PL197569B1/pl not_active IP Right Cessation
- 1998-09-28 PT PT04007579T patent/PT1439231E/pt unknown
- 1998-09-28 BR BR9812565-6A patent/BR9812565A/pt not_active Application Discontinuation
- 1998-09-28 JP JP2000513947A patent/JP4233214B2/ja not_active Expired - Fee Related
- 1998-09-28 JP JP2000513946A patent/JP4230659B2/ja not_active Expired - Fee Related
- 1998-09-28 AR ARP980104819A patent/AR013528A1/es active IP Right Grant
- 1998-09-28 SK SK450-2000A patent/SK286439B6/sk not_active IP Right Cessation
- 1998-09-28 EP EP98951476A patent/EP1019507B1/de not_active Expired - Lifetime
- 1998-09-28 DE DE69838188T patent/DE69838188T2/de not_active Expired - Lifetime
- 1998-09-28 PT PT98947553T patent/PT1021541E/pt unknown
- 1998-09-28 DK DK98947553T patent/DK1021541T3/da active
- 1998-09-28 AU AU97474/98A patent/AU750341B2/en not_active Ceased
- 1998-09-28 ES ES98951476T patent/ES2218860T3/es not_active Expired - Lifetime
- 1998-09-28 CN CNB988095726A patent/CN1148447C/zh not_active Expired - Fee Related
- 1998-09-28 WO PCT/EP1998/006143 patent/WO1999016877A1/en not_active Ceased
- 1998-09-28 CZ CZ20001147A patent/CZ299479B6/cs not_active IP Right Cessation
2000
- 2000-03-22 BG BG104267A patent/BG64757B1/bg unknown
- 2000-03-22 BG BG104266A patent/BG64679B1/bg unknown
- 2000-03-27 NO NO20001584A patent/NO20001584D0/no not_active Application Discontinuation
- 2000-03-28 US US09/537,858 patent/US6977071B2/en not_active Expired - Fee Related
- 2000-03-28 US US09/537,859 patent/US6905676B2/en not_active Expired - Fee Related
- 2000-03-28 NO NO20001609A patent/NO20001609D0/no unknown
- 2000-03-29 IL IL135351A patent/IL135351A/en not_active IP Right Cessation
- 2000-03-29 IL IL135352A patent/IL135352A/en not_active IP Right Cessation
2005
- 2005-03-07 US US11/072,454 patent/US7326411B2/en not_active Expired - Fee Related
- 2005-05-06 US US11/123,089 patent/US7338653B2/en not_active Expired - Fee Related
- 2005-05-18 US US11/131,221 patent/US20050220790A1/en not_active Abandoned
2007
- 2007-10-08 CY CY20071101290T patent/CY1110927T1/el unknown

Also Published As

Publication number	Publication date
EE200000152A (et)	2001-02-15
EP1439231A3 (de)	2004-12-22
DE69823218D1 (de)	2004-05-19
CN1145693C (zh)	2004-04-14
UA73080C2 (en)	2005-06-15
US6977071B2 (en)	2005-12-20
CZ299478B6 (cs)	2008-08-06
PT1439231E (pt)	2007-08-20
US20030119148A1 (en)	2003-06-26
HUP0003563A2 (hu)	2001-02-28
HUP0003505A2 (hu)	2001-02-28
NZ516027A (en)	2003-05-30
CN1233415C (zh)	2005-12-28
HK1062637A1 (en)	2004-11-19
EP1021541B1 (de)	2004-04-14
KR20010024213A (ko)	2001-03-26
DK1019507T3 (da)	2004-07-19
NO20001584L (no)	2000-03-27
EP1439231A2 (de)	2004-07-21
ZA988675B (en)	1999-11-24
SK286495B6 (sk)	2008-11-06
ZA988676B (en)	1999-12-03
CN1490049A (zh)	2004-04-21
KR100542934B1 (ko)	2006-01-11
CY1110927T1 (el)	2015-06-10
US7326411B2 (en)	2008-02-05
AU9747498A (en)	1999-04-23
BG64757B1 (bg)	2006-02-28
JP2001518296A (ja)	2001-10-16
US20030124677A1 (en)	2003-07-03
PT1021541E (pt)	2004-07-30
AR013528A1 (es)	2000-12-27
US6905676B2 (en)	2005-06-14
US7338653B2 (en)	2008-03-04
NZ503235A (en)	2002-08-28
PT1019507E (pt)	2004-06-30
CZ299479B6 (cs)	2008-08-06
EA200000378A1 (ru)	2000-10-30
BG64679B1 (bg)	2005-11-30
CZ20001146A3 (cs)	2000-09-13
BR9812394A (pt)	2000-09-12
AU9442098A (en)	1999-04-23
BG104267A (en)	2000-11-30
WO1999016877A1 (en)	1999-04-08
JP2001518297A (ja)	2001-10-16
EP1019507A1 (de)	2000-07-19
ES2287601T3 (es)	2007-12-16
ATE368742T1 (de)	2007-08-15
CA2305017A1 (en)	1999-04-08
NO20001584D0 (no)	2000-03-27
ATE263242T1 (de)	2004-04-15
CZ20001147A3 (cs)	2000-09-13
WO1999016876A1 (en)	1999-04-08
EP1439231B1 (de)	2007-08-01
CN1148447C (zh)	2004-05-05
CA2304827A1 (en)	1999-04-08
EP1021541A1 (de)	2000-07-26
DE69823218T2 (de)	2004-08-26
IL135352A (en)	2006-08-20
US20050201977A1 (en)	2005-09-15
EP0905240A1 (de)	1999-03-31
SK286439B6 (sk)	2008-10-07
HK1032426A1 (en)	2001-07-20
EA200000379A1 (ru)	2000-10-30
EA003942B1 (ru)	2003-10-30
US20050220790A1 (en)	2005-10-06
KR100560275B1 (ko)	2006-03-10
PL197569B1 (pl)	2008-04-30
HU226468B1 (en)	2008-12-29
SK4512000A3 (en)	2000-09-12
AR013529A1 (es)	2000-12-27
DE69838188D1 (de)	2007-09-13
HUP0003563A3 (en)	2005-11-28
HU226414B1 (en)	2008-11-28
DE69822856T2 (de)	2004-08-19
DK1439231T3 (da)	2007-11-05
AU750341B2 (en)	2002-07-18
KR20010024214A (ko)	2001-03-26
PL339545A1 (en)	2000-12-18
EP1019507B1 (de)	2004-03-31
JP4230659B2 (ja)	2009-02-25
EA003940B1 (ru)	2003-10-30
US20050164936A1 (en)	2005-07-28
DE69822856D1 (de)	2004-05-06
BR9812565A (pt)	2000-08-01
PL339559A1 (en)	2000-12-18
IL135351A (en)	2006-08-20
PL196427B1 (pl)	2008-01-31
CN1271385A (zh)	2000-10-25
SK4502000A3 (en)	2000-09-12
ES2218860T3 (es)	2004-11-16
ATE264390T1 (de)	2004-04-15
ES2215324T3 (es)	2004-10-01
DK1021541T3 (da)	2004-08-02
HK1032425A1 (en)	2001-07-20
EE200000151A (et)	2001-02-15
NZ503234A (en)	2002-06-28
JP4233214B2 (ja)	2009-03-04
BG104266A (en)	2000-11-30
AU750606B2 (en)	2002-07-25
EP0905241A1 (de)	1999-03-31
NO20001609L (no)	2000-03-28
CN1271386A (zh)	2000-10-25
NO20001609D0 (no)	2000-03-28
EP0906954A1 (de)	1999-04-07
HUP0003505A3 (en)	2005-11-28
DE69838188T2 (de)	2007-11-22

Publication	Publication Date	Title
UA73081C2 (en)	2005-06-15	Amino-terminally truncated mcp-2 as chemokine antagonists
MXPA00002880A (en)	2001-05-07	Amino-terminally truncated mcp-2 as chemokine antagonists
MXPA00002881A (en)	2001-05-07	Amino-terminally truncated rantes as chemokine antagonists